Quantcast
Last updated on April 24, 2014 at 13:32 EDT

Latest Placebo-controlled study Stories

2013-07-18 08:23:31

-- Significant overall survival benefit observed with radium 223 in patients who received prior treatment with docetaxel and in those who did not -- Radium 223 significantly delayed time to first symptomatic skeletal event -- All main secondary efficacy endpoints with radium 223 were met, showing clinical benefit with radium 223 in patients with castration-resistant prostate cancer and symptomatic...

2013-07-17 16:28:17

WHIPPANY, N.J., July 17, 2013 /PRNewswire/ -- Bayer HealthCare today announced that data from the pivotal Phase III ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) trial of its drug Xofigo(®) (radium Ra 223 dichloride) in castration-resistant prostate cancer (CRPC) patients with symptomatic bone metastases and no known visceral metastatic disease are published in the July 18 issue of the New England Journal of Medicine (NEJM). These data supported the U.S. Food and Drug...

2013-07-17 12:26:55

Payers are Most Receptive to Reimbursing Novel Therapies that Offer Clinical Improvements in Mean Pulmonary Arterial Pressure and Have Evidence of Utility in Multiple PAH Etiologies, According to a New Report from Decision Resources BURLINGTON, Mass., July 17, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed pulmonologists in the United States consider a drug's effect on...

2013-07-01 16:26:33

Phase IIB Study Evaluating Twelve Weeks of Continuous Dosing With NBI-98854 SAN DIEGO, July 1, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has completed recruitment in the Phase IIb clinical trial (Kinect Study) of its proprietary Vesicular Mono-Amine Transporter 2 compound, NBI-98854. The final subject will randomize this week. The design of this twelve-week Phase IIb study is a randomized, parallel, double-blind, placebo-controlled...

2013-06-17 08:29:45

RARITAN, N.J., June 17, 2013 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) today welcomes the World Health Organization (WHO) interim policy guidance on the use of bedaquiline (trade name SIRTURO(TM) in the U.S.) in the treatment of pulmonary multi-drug resistant tuberculosis (MDR-TB) as part of combination therapy in adults. The guidance culminates a rigorous review process by internal and external TB experts convened by the WHO and drew upon available Phase 2 safety and...

2013-05-03 23:15:52

Last month Prograde released its premier weight loss supplement, Metabo 223x. In an independent, double-blind study, Metabo 223x has now been shown to successfully reduce girth and raise energy levels. NORTH PALM BEACH, FL (PRWEB) May 03, 2013 Metabox 223x, the newest weight loss supplement released by Prograde Nutrition, was touted in its marketing as being science-based and effective. Now an independent study published last week in The Journal of the International Society of Sports...

2013-03-12 08:30:08

Topline Data Expected in Third Quarter 2013 as First Patient Is Treated in 500-Patient "RESET" Trial SAN DIEGO, March 12, 2013 /PRNewswire/ -- Lithera, Inc., a clinical stage pharmaceutical company focused on lifestyle and medical indications in aesthetic medicine and ophthalmology, announced today that the first patient has been treated with LIPO-202 (Salmeterol Xinafoate for Injection) in its 500-patient Phase 2b "RESET" trial. LIPO-202, Lithera's lead product candidate, is a...

2013-02-11 08:25:38

SAN DIEGO, Feb. 11, 2013 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that it has initiated dosing in a thorough QT/QTc study (TQT study) of ANX-188. Brian M. Culley, Chief Executive Officer, said: "Consistent with our guidance from October 2011 and our commitment to FDA, we have initiated this study before the end of the first quarter. We were pleased with the discussion we had with the Agency on the study protocol and our agreement on the...

2013-01-02 08:23:46

SANTA CRUZ, Calif., Jan. 2, 2013 /PRNewswire-USNewswire/ -- The following is being issued by the Multidisciplinary Association for Psychedelic Studies (MAPS): Subjects with chronic, treatment-resistant posttraumatic stress disorder experienced clinically meaningful improvements and no evidence of harm after participating in a small Swiss study evaluating MDMA-assisted psychotherapy, according to a paper published yesterday in the Journal of Psychopharmacology. The study used a low dose of...

2012-12-31 08:21:49

TITUSVILLE, N.J., Dec. 31, 2012 /PRNewswire/ -- Janssen Therapeutics, Division of Janssen Products, LP, today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval to SIRTURO(TM) (bedaquiline) Tablets for the treatment of pulmonary multi-drug resistant tuberculosis (MDR-TB) as part of combination therapy in adults. The accelerated approval is based on the surrogate endpoint of time to sputum culture conversion. "SIRTURO(TM) was first discovered in our...